Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

140,451 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Afatinib in Osimertinib-Resistant EGFR ex19del/T790M/P794L Mutated NSCLC.
van Kempen LC, Wang H, Aguirre ML, Spatz A, Kasymjanova G, Vilacha JF, Groves MR, Agulnik J, Small D. van Kempen LC, et al. Among authors: wang h. J Thorac Oncol. 2018 Sep;13(9):e161-e163. doi: 10.1016/j.jtho.2018.04.020. Epub 2018 Apr 25. J Thorac Oncol. 2018. PMID: 29704676 Free article. No abstract available.
Analysis of the Genomic Landscape in ALK+ NSCLC Patients Identifies Novel Aberrations Associated with Clinical Outcomes.
Couëtoux du Tertre M, Marques M, Tremblay L, Bouchard N, Diaconescu R, Blais N, Couture C, Pelsser V, Wang H, Higenell V, Izzi L, Gambaro K, Hoffert C, Srivastava A, Spatz A, Rousseau C, McNamara S, Cohen V, Batist G, Agulnik J. Couëtoux du Tertre M, et al. Among authors: wang h. Mol Cancer Ther. 2019 Sep;18(9):1628-1636. doi: 10.1158/1535-7163.MCT-19-0105. Epub 2019 Jun 26. Mol Cancer Ther. 2019. PMID: 31243098 Clinical Trial.
Fit-For-Purpose PD-L1 Biomarker Testing For Patient Selection in Immuno-Oncology: Guidelines For Clinical Laboratories From the Canadian Association of Pathologists-Association Canadienne Des Pathologistes (CAP-ACP).
Cheung CC, Barnes P, Bigras G, Boerner S, Butany J, Calabrese F, Couture C, Deschenes J, El-Zimaity H, Fischer G, Fiset PO, Garratt J, Geldenhuys L, Gilks CB, Ilie M, Ionescu D, Lim HJ, Manning L, Mansoor A, Riddell R, Ross C, Roy-Chowdhuri S, Spatz A, Swanson PE, Tron VA, Tsao MS, Wang H, Xu Z, Torlakovic EE; Canadian Association of Pathologists-Association Canadienne Des Pathologistes’ National Standards Committee for High Complexity Testing (CAP-ACP NSCHCT). Cheung CC, et al. Among authors: wang h. Appl Immunohistochem Mol Morphol. 2019 Nov/Dec;27(10):699-714. doi: 10.1097/PAI.0000000000000800. Appl Immunohistochem Mol Morphol. 2019. PMID: 31584451 Free PMC article.
Discovery of a putative blood-based protein signature associated with response to ALK tyrosine kinase inhibition.
Couëtoux du Tertre M, Marques M, McNamara S, Gambaro K, Hoffert C, Tremblay L, Bouchard N, Diaconescu R, Blais N, Couture C, Pelsser V, Wang H, McIntosh L, Hindie V, Parent S, Cortes L, Breton YA, Pottiez G, Croteau P, Higenell V, Izzi L, Spatz A, Cohen V, Batist G, Agulnik J. Couëtoux du Tertre M, et al. Among authors: wang h. Clin Proteomics. 2020 Feb 7;17:5. doi: 10.1186/s12014-020-9269-6. eCollection 2020. Clin Proteomics. 2020. PMID: 32055239 Free PMC article.
Canadian Multicenter Project on Standardization of Programmed Death-Ligand 1 Immunohistochemistry 22C3 Laboratory-Developed Tests for Pembrolizumab Therapy in NSCLC.
Torlakovic E, Albadine R, Bigras G, Boag A, Bojarski A, Cabanero M, Camilleri-Broët S, Cheung C, Couture C, Craddock KJ, Cutz JC, Dhamanaskar P, Fiset PO, Hossain M, Hwang DM, Ionescu D, Itani D, Kelly MM, Kwan K, Lim HJ, Nielsen S, Qing G, Sekhon H, Spatz A, Waghray R, Wang H, Xu Z, Tsao MS. Torlakovic E, et al. Among authors: wang h. J Thorac Oncol. 2020 Aug;15(8):1328-1337. doi: 10.1016/j.jtho.2020.03.029. Epub 2020 Apr 15. J Thorac Oncol. 2020. PMID: 32304736 Free article.
140,451 results
You have reached the last available page of results. Please see the User Guide for more information.